The estimated Net Worth of Christine Cournoyer is at least 527 千$ dollars as of 12 November 2020. Ms. Cournoyer owns over 2,303 units of Caredx Inc stock worth over 242,990$ and over the last 5 years she sold CDNA stock worth over 0$. In addition, she makes 283,594$ as Independent Director at Caredx Inc.
Christine has made over 2 trades of the Caredx Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently she bought 2,303 units of CDNA stock worth 22,086$ on 12 November 2020.
The largest trade she's ever made was buying 2,833 units of Caredx Inc stock on 10 November 2020 worth over 27,848$. On average, Christine trades about 132 units every 0 days since 2019. As of 12 November 2020 she still owns at least 8,517 units of Caredx Inc stock.
You can see the complete history of Ms. Cournoyer stock trades at the bottom of the page.
Christine M. Cournoyer serves as Independent Director of the Company. From 2012 to 2019, Ms. Cournoyer served as the Chairperson and Chief Executive Officer for N-of-One, Inc., a leading company in precision medicine delivering clinical and molecular decision support for targeted therapies decisions based on a cancer patient’s molecular profile. Prior to joining N-of-One, Ms. Cournoyer was the Vice President of Clinical Analytics at Optum, responsible for clinical electronic health records solutions and clinical decision support solutions. Prior to joining Optum through the acquisition of Picis, Inc. in 2010, Ms. Cournoyer was the President and Chief Operating Officer for Picis, a company in the healthcare IT market offering digital solutions to automate the clinical and revenue cycle workflows for the high acuity operations of hospitals. Prior to Picis, Ms. Cournoyer was responsible for all analytical solutions serving the retail industry at Harte Hanks, Inc. Ms. Cournoyer has also held roles at Lotus and IBM. At Lotus she was the Chief Information Officer. At IBM she was Vice President of Global Business Transformation, responsible for driving the digital strategy for global software fulfillment for the $8B software business. Ms. Cournoyer has served on a variety of boards over the last 20 years, including The Stride Rite Corporation, GTECH Corporation, BJ’s Wholesale Club, Inc. and Emerson Hospital. Ms. Cournoyer holds a B.S in Business Administration from University of Massachusetts, an M.A. in Economics from Northeastern University and has attended MIT’s Executive Education Program.
As the Independent Director of Caredx Inc, the total compensation of Christine Cournoyer at Caredx Inc is 283,594$. There are 10 executives at Caredx Inc getting paid more, with Peter Maag having the highest compensation of 8,855,740$.
Christine Cournoyer is 68, she's been the Independent Director of Caredx Inc since 2019. There are 1 older and 15 younger executives at Caredx Inc. The oldest executive at Caredx Inc is Ralph Snyderman, 80, who is the Independent Director.
Christine's mailing address filed with the SEC is C/O CAREDX, INC., 8000 MARINA BOULEVARD, BRISBANE, CA, 94005.
Over the last 10 years, insiders at Caredx Inc have traded over 60,271,359$ worth of Caredx Inc stock and bought 1,726,634 units worth 9,072,700$ . The most active insiders traders include Group Holdings (Sbs) Adviso...、Neil Gagnon、Peter Maag. On average, Caredx Inc executives and independent directors trade stock every 17 days with the average trade being worth of 615,506$. The most recent stock trade was executed by Alexander L Johnson on 20 August 2024, trading 61,023 units of CDNA stock currently worth 1,432,820$.
caredx: transforming transplant patient care through novel surveillance management solutions caredx, inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. by combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, caredx is at the forefront of organ transplant surveillance and pre-transplant hla typing solutions. nasdaq:cdna about allosure® allosure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. allosure is a clinical-grade, proprietary next-generation sequencing (ngs) based test to detect donor-derived cell-free dna (dd-cfdna) in order to identify organ injury in kidney transplant recipients. allosure is analytically validated as a sensitive, specific, and precise measurement of dd-cfdna. allos
Caredx Inc executives and other stock owners filed with the SEC include: